Kjellin M., Wesslén T., Löfblad E., Lennerstrand J., and Lannergård A., “The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort”, ujms, vol. 123, no. 1, pp. 50–56, Mar. 2018.